April 20, 2022action, analysis, analytics, approval, approved, business, Business Analysis, cannabidiol, cannabis, cbd, claim, compliance, Concentrates & Extracts, consumer, Coronavirus, COVID, COVID-19, cultivation, drug, Edibles & Processing, enforcement, extraction, farm bill, FD&C act, FDA, Federal, government, growing, Health, industry, lab, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, medical, medicine, New, product, Product Development, Quality, regulation, regulations, regulatory, research, retail, safety, state, test, Testing, thc, threaten, U.S. Food and Drug Administration, unapproved, unsubstantiated, warning, wellness FDA Warning Letters: Stop Claiming CBD Prevents COVID Once again, the U.S. Food and Drug Administration (FDA) has issued a number of warning letters to companies selling hemp-derived cannabidiol (CBD) […]